Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 48-Hour nerve block prevent the 'Rebound Pain' after shoulder surgery?

NCT ID NCT07770165

Symptom relief Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This trial tests whether a continuous nerve block lasting 48 hours can reduce the sharp 'rebound pain' that often strikes after a single-shot nerve block wears off following shoulder replacement surgery. Half of the participants will receive the continuous block through a small catheter, while the other half gets a standard one-time injection. Researchers will track pain scores and opioid use for 96 hours after surgery to see if the longer-lasting block offers better pain control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous interscalene nerve block with ropivacaine 0.2% for 48 hours
What this could lead to
If effective, a continuous nerve block could become a standard way to prevent severe rebound pain after shoulder replacement, improving recovery and reducing opioid use.
What could go wrong
The trial is relatively small and early, and results may not apply to all patients. There are also risks associated with nerve blocks, such as infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 154 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged \>18 years of age * ASA I-III * Scheduled for elective ambulatory total shoulder arthroplasty. Exclusion Criteria: * ASA IV * Revision surgery * Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection) * Preoperative chronic pain or opioid use * Preoperative drug dependency * Severe respiratory disease or contralateral diaphragmatic paralysis * Patient refusal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interscalene analgesia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interscalene analgesia Interscalene blocks Interscalene nerve block Locoregional anaesthesia Orthopedic surgery patients Rebound pain Reverse total shoulder arthroplasty Total shoulder arthroplasty

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • South Health Campus

    Calgary, Alberta, T3M 1M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.